CN104435995A - Application of tsaoko amomum fruit to preparation of traditional Chinese veterinary medicine for treating and/or preventing colibacillosis - Google Patents
Application of tsaoko amomum fruit to preparation of traditional Chinese veterinary medicine for treating and/or preventing colibacillosis Download PDFInfo
- Publication number
- CN104435995A CN104435995A CN201410828727.9A CN201410828727A CN104435995A CN 104435995 A CN104435995 A CN 104435995A CN 201410828727 A CN201410828727 A CN 201410828727A CN 104435995 A CN104435995 A CN 104435995A
- Authority
- CN
- China
- Prior art keywords
- preparation
- medicine
- colibacillosis
- dosage
- chicken
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses application of tsaoko amomum fruit to preparation of a traditional Chinese veterinary medicine for treating and/or preventing colibacillosis, and also provides the traditional Chinese veterinary medicine for treating and/or preventing poultry colibacillosis. The medicine is a preparation which is prepared from the tsaoko amomum fruit serving as an active ingredient and pharmaceutically acceptable auxiliary materials or auxiliary ingredients, wherein the administration dosage of the preparation is 0.5-2g/kg d. The tsaoko amomum fruit can be used for effectively treating and preventing chicken colibacillosis at low administration dosage and can be used for substituting an antibiotic, and a new, safe and effective medicine selection is provided for clinical administration.
Description
Technical field
The present invention relates to Fructus Tsaoko and prepare the purposes treated and/or prevented in the herbal medicine of colibacillosis.
Background technology
Colibacillosis is one group of disease caused by Escherichia coli, and various livestock and poultry has this sick, particularly young stock very susceptible, normal generation severe diarrhea and septicemia, affect growth promoter, severe patient causes death, carrys out great economic loss to cultivation industrial belt.
Chicken colibacillosis is the acute or chronic infectious disease of the one of the chicken caused by pathological form escherichia coli.Because the age in days of infected chicken, resistance, escherichia coli pathogenicity are different with route of infection and can by many symptoms sick type different with pathological changes, as embryo, young bird death and omphalitis, acute sepsis, airsacculitis, yolk peritonitis, escherichia coli salpingitis, enteritis, escherichia coli granuloma, more than ten sick types such as escherichia coli encephalopathy and panophthalmitis.There are the generation of primary disease and popular in all poultry husbandries developed regions, the world and country, and have more and more serious tendency.Also there is the generation of primary disease and popular in China, near especially during the last ten years, escherichia coli have become one of Infectious Diseases of serious harm poultry husbandry.
At present, prevent and treat colibacillosis and usually adopt the antimicrobial drugs such as antibiotic, cause the generation of multi-drug resistant bacteria, treatment cost increases, and treatment difficulty strengthens, what is more important, and antibacterials are residual serious in muscle, internal organs and egg, very big to food safety hazard.Chinese medicine, as the precious legacy of motherland's medical science, has unique resources advantage, and toxic and side effects little, not easily develop immunity to drugs.
Fructus Tsaoko is the dry mature fruit of zingiberaceous plant Fructus Tsaoko Amomum tsao-ko Crevost et Lemaire.Acrid in the mouth, warm in nature, return spleen, stomach warp.Have dampness warming middle-JIAO, the function of preventing the attack (or recurrence) of malaria expectorant, for internal retention of cold wetness, abdominal distention, feeling of fullness is vomitted, malaria cold and heat, and pestilence is generated heat.
Research shows, Fructus Tsaoko has the effect of analgesia, anti-gastric-ulcer, anti-hepatitis virus, may be used for disease such as treatment hepatitis B, abdominal post-operation abdominal distention etc.In addition, Fructus Tsaoko also has the effect of non-oxidizability, antimutagenic, mildew-resistant, has no the report of its treatment colibacillosis of report.
Summary of the invention
Technical scheme of the present invention there is provided the novelty teabag of Fructus Tsaoko in the herbal medicine of preparation treatment colibacillosis.
The invention provides the purposes of Fructus Tsaoko in the herbal medicine of preparation treatment colibacillosis.
Wherein, the herbal medicine of described treatment colibacillosis is the medicine for the treatment of poultry colibacillosis.
Poultry, refers to the birds manually fed, and mainly for obtaining its meat, ovum and feather, also has as other use, as carrier pigeon, house pet etc.Be generally Phasianidae and Anatidae animal, as chicken, duck, goose etc., also have the birds of other sections as turkey, Columba livia, Carnis Coturnicis japonicae and various song bird.
Preferably, described medicine is active component with Fructus Tsaoko, and add the preparation that pharmaceutically acceptable adjuvant or complementary composition are prepared from, the dosage of described preparation is 0.5 ~ 2g/kgd.Further preferably, the dosage of described preparation is 0.5g/kgd.
Wherein, described preparation is liquid preparation, gaseous formulation, solid preparation or semi-solid preparation.Described solid preparation is powder.
Present invention also offers a kind of herbal medicine for the treatment of chicken colibacillosis, it is active component with Fructus Tsaoko, and add the preparation that pharmaceutically acceptable adjuvant or complementary composition are prepared from, the dosage of described preparation is 0.5 ~ 2g/kgd.
Preferably, the dosage of described preparation is 0.5g/kgd.
Described preparation is liquid preparation, gaseous formulation, solid preparation or semi-solid preparation.Described solid preparation is powder.
Fructus Tsaoko of the present invention effectively can suppress escherichia coli, and treatment and prevention chicken colibacillosis, when dosage is low to moderate 0.5g/kgd, the excellent effect for the treatment of chicken colibacillosis, can be used for substitute antibiotics, side effect is little, production cost is low, and potential applicability in clinical practice is good.
Obviously, according to foregoing of the present invention, according to ordinary technical knowledge and the customary means of this area, not departing under the present invention's above-mentioned basic fundamental thought prerequisite, the amendment of other various ways, replacement or change can also be made.
The detailed description of the invention of form by the following examples, is described in further detail foregoing of the present invention again.But this should be interpreted as that the scope of the above-mentioned theme of the present invention is only limitted to following example.All technology realized based on foregoing of the present invention all belong to scope of the present invention.
Detailed description of the invention
The preparation of embodiment 1 medicine of the present invention
Get Fructus Tsaoko, pulverize, add pharmaceutically acceptable adjuvant or complementary composition, to obtain final product.
Beneficial effect of the present invention is proved further below by way of pharmacodynamics test.
Test example 1 effect experiment
1 material and instrument
1.1 medicine
Invention medicine: Fructus Tsaoko.
1.2 experimental strain
Escherichia coli Quality-control strains ATCC25922, escherichia coli type strain CMCC (B) 44102, Clinical Isolates of Escherichia Coli 18 strain.
1.3 laboratory animal
Mice (SPF level) [Chengdu University of Traditional Chinese Medicine's Animal Experimental Study center, production licence number: SCXK (river) 2008-11 use the quality certification number: SCXK (river) 2008-049].
The yellow chicken in thought's chicken house 1 age in days Nanjing.
1.4 culture medium, reagent and consumptive material
Mueller-Hinton agar (OXOID, lot number: 729683), Mucin from porcine stomach, Type II (SIGMA, lot number: 108k0010), Nutrient agar (Beijing extensive and profound in meaning star biotechnology Co., Ltd, lot number: 20082502), Mcfarland Standard (bioMeri é ux, Inc. lot number: 821772701) etc.
1.5 experimental apparatus
Multiple spot inoculation instrument (Japan's assistant makes institute, SAKUMA MIT-P type for a long time), use for laboratory autoclave (SANYO, MLS-3780 type), CO
2iNCUBATOR (SANYO, MOC-15A), energy-saving and purifying workbench (Chengdu new light Fei Lante cleaning project company limited).
2 test methods
The preparation of 2.1 invention medicines
Fructus Tsaoko is ground into fine powder, for subsequent use after sieving.
The antibacterial activity in vitro of 2.2 invention medicines
Bacterium liquid configures: the logarithmic (log) phase strain subject physiological saline solution of incubated overnight is adjusted to bacterial concentration 1.5 × 10
6cFU/ml.
The preparation of pastille flat board: weigh invention medicine 4.5g, 3g, 1.5g, 0.75g, 0.375g, 0.188g respectively in disposable sterilized plate, for subsequent use after adding the mixing of 15ml sterilizing MH culture medium, the dilution gradient of each medicine in flat board is respectively 300mg/ml ~ 12.5mg/ml.Positive control flat board is prepared to add normal saline alternatives to medication in flat board.
In Vitro Bacteriostatic mensuration and result judge: adopt multiple spot inoculation instrument the bacterium liquid of experimental strain to be added pastille flat board and the positive control flat board of variable concentrations gradient, and replace bacterium liquid to make negative control with normal saline.37 DEG C of constant temperature culture 18 ~ 24h, observe each bacterial strain and are containing the growing state in variable concentrations gradient Drug plates.With the Cmin without medicine in bacterial growth flat board for this reason medicine to the minimum inhibitory concentration (MIC) of this bacterial strain.
In 2.3 invention medicine bodies, anti-escherichia coli is active
The mensuration of Strain Virulence: by escherichia coli ATCC25922 in 37 DEG C of constant temperature culture to logarithmic (log) phase, adopts 2 times of dilution method normal saline to dilute it respectively, is configured to the bacterium liquid of variable concentrations gradient.The bacterium liquid getting 1 part of dilution mixes with 1 part of 10% gastric Mucin, carries out lumbar injection, and do negative control with 5% gastric Mucin to mice.Under the prerequisite that control mice is not dead, record the mortality rate in each dosage group mice 24 ~ 48h, measure the minimum amount of bacteria (dilution factor) that SPF mice is all dead, i.e. the minimum lethal dose (MLD) of this bacterium liquid.
Anti-escherichia coli activity test in body: experiment is divided into 2 groups, i.e. blank group and invention medicine group.The KM mice (SPF) of choice criteria body weight, male and female half and half, often organize mice 10, the wherein experimental group special feed that every day, free choice feeding prepared, blank group free choice feeding does not add the normal feedstuff of invention medicine, and feed 21d continuously, and every 7d weighs to mice, observe invention medicine to the impact of Mouse Weight and toxic reaction thereof, observe the feed intake of mice and the palatability of feedstuff simultaneously.21d escherichia coli carries out counteracting toxic substances, the survival rate after statistical analysis counteracting toxic substances in mice 72h.Feed with the basal diet not adding invention medicine and not counteracting toxic substances for blank group; With basal diet feed to carry out after 21d counteracting toxic substances for model group, with inject not containing 5% gastric Mucin of escherichia coli for gastric Mucin matched group.
Data statistics: every 7d carries out mouse weights, observes the impact that invention medicine increase weight on mice, and the death of mice or number of surviving in 72h after counteracting toxic substances, adds up its survival rate.
The clinical trial of 2.4 invention Drug therapy chicken escherichia coli diseases
Experiment grouping: choose the 1 yellow chicken in age in days Nanjing, adaptability is fed 6d, and 7 ages in days are divided into 5 groups at random, i.e. the high, medium and low dosage group of invention medicine, blank group and model group, often organize 18.
The mensuration of Strain Virulence: by experimental strain in 37 DEG C of constant temperature culture to logarithmic (log) phase, 2 times of dilution method normal saline are adopted to dilute it respectively, be configured to the bacterium liquid of variable concentrations gradient, intramuscular injection carried out to the yellow chicken in 21 age in days Nanjing, and does negative control with normal saline.Under the prerequisite that matched group is not dead, in record 24 ~ 48h, the mortality rate of chicken, measures the minimum amount of bacteria (dilution factor) that chicken is all dead, i.e. the minimum lethal dose of this bacterium liquid.
The sick curative effect of invention medicine treatment chicken escherichia coli: Fructus Tsaoko fine powder is mixed in normal feedstuff with the ratio of 4% (high dose group), 2% (middle dosage group), 1% (low dose group) respectively, blank group and model group are fed not containing the normal feedstuff of invention medicine, allow chicken free choice feeding, every 7d weighs to each group of chicken, feed 14d continuously, the minimum lethal dose of 14d escherichia coli ATCC25922 carries out counteracting toxic substances, observe the impact that invention medicine increases weight on experimental chicken, and the curative effect of invention medicine treatment chicken escherichia coli disease.
3 experimental results
The In Vitro Bacteriostatic of 3.1 invention medicines
Adopt agar plate dilution method to determine the MIC of invention medicine to 20 strain escherichia coli type strains and clinical separation strain, the results are shown in Table 1.
Table 1: invention medicine is to the In Vitro Bacteriostatic of escherichia coli
As seen from the above table, medicine of the present invention has identical bacteriostatic activity to all tested escherichia coli type strains and clinical separation strain, and MIC is 300mg/ml.
3.2 invention medicines are on the impact of Mouse Weight
Respectively before administration, after administration, 7d, 14d and 21d weigh to each group of mice, and SPSS software statistics analyzes each group of Mouse Weight, the results are shown in Table 2.
Table 2: invention medicine is on the impact of Mouse Weight
As seen from the above table, invention medicine is mixed in feedstuff the mice 21d that feeds continuously, and mice is without any untoward reaction, and mice Gain weight is totally good.Compare with naive mice, experimental mice body weight in different time sections all without obvious significant difference.Invention medicine is described to mice without any toxicity and untoward reaction, effectively can makes an addition in feedstuff and feed.
In 3.3 invention medicine bodies, anti-escherichia coli infects curative effect
Be mixed into by invention medicine in mice basal diet, mice 21d, 21d MLD escherichia coli bacterium liquid of feeding continuously carries out counteracting toxic substances to mice, and after statistics counteracting toxic substances, the survival rate of mice in 72h, the results are shown in Table 3.
Table 3: in invention medicine body, anti-escherichia coli infects curative effect
As seen from the above table, medicine of the present invention makes an addition in feedstuff mice of feeding, and have obvious Ti Nei Chinese People's Anti-Japanese Military and Political College intestinal dust bacterial activity, can obviously extend the mouse survival time, in 72h, mouse survival rate is 30.0%.
3.4 invention medicines are on the impact of chicken body weight
Respectively before administration (0d), after administration, the body weight of 7d and 14d to each group of chicken is weighed, and analyzes each group of Mouse Weight change, the results are shown in Table 4 by SPSS software statistics.
Table 4: invention medicine is on the impact of chicken body weight
As seen from the above table, with the chicken weight ratio of blank group comparatively, invention medicine high, medium and low dosage group is before administration all without obvious significant difference; 7d upon administration, except the more blank group of average weight of dosage group in invention medicine is partially light, the average body weight average of invention medicine high and low dose group higher than blank group, but compares between each group mutually, all without obvious significant difference (P > 0.05); 14d upon administration, the average body weight average of high, medium and low dosage group higher than the average weight of blank group, but compares between each group, mutually all without obvious significant difference.
Experimental result illustrates, Fructus Tsaoko of the present invention has no side effect to chicken growth, can increase the body weight of chicken on the contrary to a certain extent.
The curative effect of 3.5 invention medicine treatment chicken escherichia coli diseases
Respectively from early stage feed blank group of 14d, high dose group, Stochastic choice 10 chickens carry out clinical trial middle dosage group and low dose group, namely with the MLD escherichia coli bacterium liquid of prerun, counteracting toxic substances is carried out to each group of chicken, add up the survival rate of chicken in 48h and 7d after counteracting toxic substances respectively, the results are shown in Table 5.
Table 5: the curative effect of invention medicine treatment chicken escherichia coli disease
As seen from the above table:
1, compared with matched group, the survival rate of high, medium and low 3 the dosage groups of medicine of the present invention all significantly improves, and illustrates that Fructus Tsaoko of the present invention has significantly treatment and preventive effect to chicken escherichia coli disease;
2, compared with height, middle dosage, the dosage of low dose group of the present invention is minimum, but effect is excellent all the better.
The dosage of the high, medium and low dosage group of medicine of the present invention is respectively 2g/kgd, 1g/kgd, 0.5g/kgd.
Therefore, when adopting Fructus Tsaoko of the present invention to treat or prevent chicken colibacillosis, dosage is 0.5 ~ 2g/kgd, preferred 0.5g/kgd.
To sum up, Fructus Tsaoko of the present invention effectively can suppress escherichia coli, treatment and prevention chicken colibacillosis, wherein, when dosage is 0.5g/kgd, and excellent effect.
Claims (10)
1. Fructus Tsaoko is preparing the purposes treated and/or prevented in the herbal medicine of colibacillosis.
2. purposes according to claim 1, is characterized in that: described in treat and/or prevent colibacillosis herbal medicine be the herbal medicine treating and/or preventing poultry colibacillosis.
3. purposes according to claim 1 and 2, is characterized in that: described herbal medicine is active component with Fructus Tsaoko, and add the preparation that pharmaceutically acceptable adjuvant or complementary composition are prepared from, the dosage of described preparation is 0.5 ~ 2g/kgd.
4. purposes according to claim 3, is characterized in that: the dosage of described preparation is 0.5g/kgd.
5. the purposes according to claim 3 any one, is characterized in that: described preparation is liquid preparation, gaseous formulation, solid preparation or semi-solid preparation.
6. purposes according to claim 5, is characterized in that: described solid preparation is powder.
7. treat and/or prevent a herbal medicine for poultry colibacillosis, it is characterized in that: it is active component with Fructus Tsaoko, and add the preparation that pharmaceutically acceptable adjuvant or complementary composition are prepared from, the dosage of described preparation is 0.5 ~ 2g/kgd.
8. herbal medicine according to claim 7, is characterized in that: the dosage of described preparation is 0.5g/kgd.
9. herbal medicine according to claim 7, is characterized in that: described preparation is liquid preparation, gaseous formulation, solid preparation or semi-solid preparation.
10. herbal medicine according to claim 9, is characterized in that: described solid preparation is powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410828727.9A CN104435995B (en) | 2014-12-25 | 2014-12-25 | Purposes of the tsaoko in preparing treatment and/or preventing the herbal medicine of colibacillosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410828727.9A CN104435995B (en) | 2014-12-25 | 2014-12-25 | Purposes of the tsaoko in preparing treatment and/or preventing the herbal medicine of colibacillosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104435995A true CN104435995A (en) | 2015-03-25 |
| CN104435995B CN104435995B (en) | 2018-09-18 |
Family
ID=52883256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410828727.9A Expired - Fee Related CN104435995B (en) | 2014-12-25 | 2014-12-25 | Purposes of the tsaoko in preparing treatment and/or preventing the herbal medicine of colibacillosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104435995B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103341114A (en) * | 2009-12-28 | 2013-10-09 | 成都中医药大学 | Application of amomum tsao-ko oil in preparation of drugs for treating bacterial infectious diseases |
| CN103394016A (en) * | 2010-12-28 | 2013-11-20 | 成都中医药大学 | Application of Amomum tsao-ko oil to preparation of medicament for treating bacterial infectious disease |
-
2014
- 2014-12-25 CN CN201410828727.9A patent/CN104435995B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103341114A (en) * | 2009-12-28 | 2013-10-09 | 成都中医药大学 | Application of amomum tsao-ko oil in preparation of drugs for treating bacterial infectious diseases |
| CN103394016A (en) * | 2010-12-28 | 2013-11-20 | 成都中医药大学 | Application of Amomum tsao-ko oil to preparation of medicament for treating bacterial infectious disease |
Non-Patent Citations (2)
| Title |
|---|
| 代敏: "5味化湿药对奶牛乳腺炎病原菌体外抗菌活性的比较", 《江苏农业科学》 * |
| 褚秀玲: "中药抗大肠杆菌病研究进展", 《安徽农业科学》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104435995B (en) | 2018-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103006792A (en) | Veterinary drug for preventing livestock bowel diseases, preparation method of drug, and feed | |
| CN101879172B (en) | Compound preparation of ceftiofur sodium | |
| CN102058821A (en) | Application of tsaoko oil in preparation of medicament for treating bacterial infection diseases | |
| CN103006820A (en) | Chinese medicinal composition with functions of clearing heat and drying dampness and preparation method thereof | |
| CN109568301A (en) | A kind of gallic acid, Rhein compound prescription preparation method and applications | |
| CN103070907B (en) | Medicine resistant to poultry coccidiosis and preparation method thereof | |
| CN106554385B (en) | Polypeptide compound and application thereof in livestock and poultry | |
| CN102048059B (en) | Feed additive used for preventing and treating vibrio gill-rot disease of aquatic animals and preparation method thereof | |
| CN104435995A (en) | Application of tsaoko amomum fruit to preparation of traditional Chinese veterinary medicine for treating and/or preventing colibacillosis | |
| CN105831391B (en) | Traditional Chinese medicine micro-ecological granules for preventing and treating newcastle disease, feed and application thereof | |
| CN107789394B (en) | Composition for treating livestock and poultry diarrhea | |
| CN102293764B (en) | New application of p-hydroxycinnamic acid | |
| CN105724826A (en) | Prawn feed additive and application thereof | |
| CN105126081A (en) | Chinese and Western medicine composition for chicken feeding and preparation method of composition | |
| CN102266346B (en) | Medicament for preventing and controlling coccidiosis | |
| CN101780064B (en) | New application of p-hydroxyl cinnamic acid | |
| CN104688729B (en) | Kainic acid application in preparing anti-Cryptosporidium baileyi medicine | |
| CN110150486A (en) | A kind of feed addictive for preventing and treating the intestines problems such as milking sow constipation diarrhea | |
| CN104306629B (en) | A kind of Chinese medicine composition of chicken colibacillosis resisting disease and preparation method thereof | |
| CN102240335B (en) | Compound salinomycin preparation | |
| CN109394881A (en) | Prevent and treat pure Chinese medicine composition of poultry enterotoxin syndrome and preparation method thereof and application method | |
| CN114736875B (en) | Riemerella anatipestifer phage, phage composition and application thereof | |
| CN117264910B (en) | Phage resistant to Gao Wenan spectrum salmonella and clinical application thereof | |
| CN108096256B (en) | Cedrelone is preparing the application in anti-Cryptosporidium baileyi drug | |
| CN102151278B (en) | Use of 2-deoxy-D-glucose in prevention and treatment of viral diseases in livestock |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180918 Termination date: 20201225 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |